<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151319</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-CORE 002</org_study_id>
    <nct_id>NCT01151319</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults</brief_title>
  <acronym>HIV-CORE 002</acronym>
  <official_title>A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety
      and immunogenicity of three novel HIV vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Actively collected data throughout the study until 6 months after the last vaccination</time_frame>
    <description>Proportion of volunteers who develop a grade 3 or 4 local reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Samples will be collected at every visit pre- and post vaccination</time_frame>
    <description>Proportion of volunteers who develop new CD8+ and CD4+ T cell responses to one or more HIV-1 epitopes, as determined by IFN-γ ELISPOT assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Stage 1; screen, 0, 1, 2, 4, 8, 16, 28 wk. Stage 2; screen, 0, 1, 2, 4, 8, 9, 12, 20, 28 wk. Stage 3; screen, 1, 8, 12, 13, 14, 20, 21, 22, 28 wk. Stage 4; screen, 0, 8, 12, 13, 16, 17, 18, 24, 28 wk post vac. Stage 2 &amp; 3: 6,12,24 mth after last vaccine</time_frame>
    <description>Exploration of the efficacy of vaccine-induced CD8+ T cells to suppress HIV-1 replication in vitro.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>Stage 1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Time-course matched to vaccinations (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdV63.HIVconsv low dose.</intervention_name>
    <description>Attenuated chimp adenovirus. 5x10^9 virus particles.</description>
    <arm_group_label>Stage 1.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdV63.HIVconsv high dose.</intervention_name>
    <description>Attenuated chimp adenovirus at 5x10^10 virus particles.</description>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pSG2.HIVconsv</intervention_name>
    <description>DNA at 4mg per dose.</description>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA.HIVconsv</intervention_name>
    <description>Attenuated poxvirus at 4x10^8 plaque forming units per dose.</description>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_label>Stage 3</arm_group_label>
    <arm_group_label>Stage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline</description>
    <arm_group_label>Stage 2 Placebo</arm_group_label>
    <arm_group_label>Stage 3 placebo</arm_group_label>
    <arm_group_label>Stage 4 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females, as assessed by a medical history, physical examination and
             laboratory tests.

          2. Aged at least 18 years on the day of screening and no greater than 50 years on the day
             of the first vaccination.

          3. Willing to comply with the requirements of the protocol and available for follow-up
             for the planned duration of the study.

          4. In the opinion of the principal investigator or designee, the volunteer has understood
             the information provided. Written informed consent must be given before any
             study-related procedures are performed.

          5. Willing to undergo HIV-1 testing, HIV-1 counselling and receive HIV-1 test results.

          6. If heterosexually active female; using an effective method of contraception (e.g.
             hormonal contraception, diaphragm, intra-uterine device (IUD), condoms, anatomical
             sterility in self or partner) from 14 days prior to the first vaccination until at
             least 6 weeks after the last vaccination; all female volunteers must be willing to
             undergo urine pregnancy tests at time points specified in the protocol.

          7. If heterosexually active male; willing to use an effective method of contraception
             (condoms; anatomical sterility in self or partner) from the day of the first
             vaccination until 6 weeks after the last vaccination.

          8. Willing to forgo donations of blood during the study.

        Exclusion Criteria:

          1. Any clinically significant acute or chronic medical condition that is considered
             progressive or, in the opinion of the principal investigator or designee, would make
             the volunteer unsuitable for the study.

          2. Any of the following abnormal laboratory parameters listed below:

             Haematology

               -  Haemoglobin &lt; 10.0 g/dl

               -  Absolute Neutrophil Count (ANC) ≤ 1000 /mm3 (≤ 1 x 109 /l)

               -  Absolute Lymphocyte Count (ALC) ≤ 600 /mm3 (≤ 1 x 109 /l)

               -  Platelets ≤100,000 /mm3, ≥ 550,000 /mm3 (≤ 90 /l, ≥ 550 /l) Biochemistry

               -  Creatinine &gt; 1.3 x ULN

               -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN

               -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN Urinalysis

               -  Abnormal dipstick confirmed by microscopy

          3. Reported high-risk behaviour for HIV infection. High-risk behaviour for HIV-1
             infection is defined as follows. Within the previous 6 months the volunteer has:

               -  Had unprotected vaginal or anal sex with a known HIV-infected person or a casual
                  partner (i.e., no continuing, established relationship)

               -  Engaged in sex work for money or drugs

               -  Used injection drugs

               -  Acquired one of the following sexually transmitted disease (STD); Chlamydia,
                  gonorrhoea and syphilis.

          4. Confirmed HIV-1 or HIV-2 infection.

          5. If female, pregnant or planning a pregnancy within 6 weeks after last vaccination; or
             lactating.

          6. Receipt of live attenuated vaccine within the previous 60 days (live attenuated flu
             vaccine within 14 days) or planned receipt within 60 days after vaccination with
             Investigational Product or receipt of other vaccine within the previous 14 days or
             planned receipt within14 days after vaccination with Investigational Product.

          7. Receipt of blood transfusion or blood products within the previous 6 months.

          8. Participation in another clinical trial of an Investigational Product currently,
             within the previous 3 months or expected participation during this study.

          9. Receipt of any investigational HIV vaccine within the last 6 years.

         10. History of severe or very severe local or systemic reactogenicity events, or history
             of severe or very severe allergic reactions.

         11. Confirmed diagnosis of hepatitis B virus (surface antigen, HBsAg), hepatitis C virus
             (HCV antibodies) or active syphilis.

         12. Smallpox vaccination within the previous 3 years (smallpox vaccination prior to 3
             years should be documented but is not an exclusion criterion).

         13. Major psychiatric illness including any history of schizophrenia or severe psychosis,
             bipolar disorder requiring therapy, suicidal attempt or ideation in the previous 3
             years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Hanke</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucy Dorrell</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 9DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

